Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros

BACKGROUND: The development of therapies for sickle cell disease has received special attention, particularly those that reduce the polymerization of hemoglobin S. Hydroxyurea is a commonly used medication because it has the ability to raise levels of fetal hemoglobin, decrease the frequency of vaso...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Fernanda Kelle de Souza, Maia, Caroline Nogueira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Hematologia e Hemoterapia 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520633/
https://www.ncbi.nlm.nih.gov/pubmed/23284256
http://dx.doi.org/10.5581/1516-8484.20110029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520633/
https://www.ncbi.nlm.nih.gov/pubmed/23284256
http://dx.doi.org/10.5581/1516-8484.20110029

Ejemplares similares